P I Industries Ltd Q4 FY2024 Concall Summary

Key Takeaways

• 15% guided growth in a soft cycle: Management guided FY25 revenue growth of 15% at the company level, calling it "quite reasonable given the not-so-positive growth scenario/sentiment of the global industry."
• Pharma is the margin story to watch: Pharma grew 25%+ but carries suppressed margins during a 1.5-year development phase; management expects normalized EBITDA margins of 20%-plus once that cycle completes.
• Export engine still running on new products: More than 70% of FY24 export growth came from new products, and the non-agchem pipeline now accounts for 50% of new enquiries, with a long-term target of up to one-third of commercializations.
• Domestic dragged by weather, not demand: A 5% Q4 domestic decline was pinned on erratic monsoon and El Nino, not structural weakness; the portfolio is in-licensed, exclusive, and management expects annual growth to resume.
• What to watch next quarter: Whether the 15% growth trajectory holds through Q1, the pace of pharma order deferment resolution, and any signal that global inventory destocking is ending in H2 as projected.

Growth Guidance & the 15% Bet

• The number: 15% revenue growth at company level for FY25, spanning domestic, CSM exports and pharma. Management framed it as cautious: the base is higher, global industry sentiment is not positive, and domestic depends on monsoon.
• Long-term ambition intact: Once the industry cycle normalizes, management sees opportunities to return to 18%-20% growth, without compromising on margin.
• New product share rising: New products are expected to grow to at least 30% of revenue over the next 3 years, up from the current undisclosed share.
• Domestic recovery assumed, not guaranteed: The domestic outlook hinges on monsoon and channel inventory clearance; Q1 is a placement quarter, with real consumption starting in H2 June and Q2.

Rajnish Sarna: "we are confident of achieving around 15% growth, which I think is quite reasonable given the not-so-positive growth scenario/sentiment of the global industry."

Pharma: The Development-Phase Margin Math

• Topline growing, bottom line waiting: Pharma is expected to grow more than 25% in FY25, but EBITDA margins are suppressed because development expenditure runs through the P&L and the investment cycle continues for at least 1.5 years.
• The margin timeline: Management committed that pharma EBITDA margin will "surely be a 20%-plus kind of level post 3 years development phase." Before development spend, the margin can move from 12% to about 14%-15% in the next two years.
• Revenue ramp-up path: The original outlook of more than doubling acquired business revenues over 3-4 years continues; post-Ind AS, Rs. 300 crore can reach Rs. 500 crore by FY26.
• Deferred orders still in play: FY24 pharma degrowth of 37% was due to supply deferment, not price decline; discussions with the customer are ongoing and supply is expected in the coming financial year or a little later.
• Capex done, development underway: Pharma capex of Rs. 1,082.3 cr including acquired assets of Rs. 497.2 cr is complete; the development phase will continue for the next 1-1.5 years.

Rajnish Sarna: "Well, this development phase will continue for the next 1-1.5 years although we will be growing more than 25% in the next financial year. In terms of margins, till the time we complete this development phase, it is difficult to clearly indicate the numbers but once we complete this development cycle in next 1.5 years or so, we expect to achieve normalized EBITDA margins."

Export Engine & the Non-Agchem Pivot

• New products drove the year: More than 70% of FY24 export growth came from new products, reflecting PI's early-stage product lifecycle commercialization model.
• Non-agchem pipeline building: Share of non-agchem molecules in new enquiries reached 50%; in the longer term, management anticipates up to one-third of new molecule commercializations from non-agchem segments including electronic chemicals, semiconductors, performance chemicals and advanced polymers.
• Infrastructure following the pipeline: One dedicated plant and one multiproduct plant for new molecules have been installed; a plant currently under construction is planned for some non-agchem products as volumes grow.
• Global demand recovery delayed: Inventory destocking globally is "seemingly incomplete," and any material improvement in demand and pricing is projected only in the later part of the current financial year.
• Patent risk contained: Pyroxasulfone going off patent in the US is not expected to have a major impact in the current fiscal; it will take a few years before another player registers, and final formulations/combinations have longer patent protection.

Mayank Singhal: "What continues to attract global innovators to PI is our demonstrated capability in process development and innovation, efficient scaleup of complex molecules, project execution capabilities and our ESG standards, above all our respect to IP."

Domestic: Weather-Hit but Structurally Sound

• The monsoon excuse is credible: Domestic revenue declined 5% in Q4 and 6% in FY24, attributed to erratic monsoon and El Nino causing long dry spells that hit insecticide and herbicide sales in certain geographies.
• Portfolio quality provides a floor: The domestic portfolio comprises in-licensed exclusive products with significant growth potential; the development pipeline includes more than 20 products in development and registration.
• Biologics gaining traction: Biologics brands grew 35% in Q4 and 29% in FY24, with horticulture specialist brand Jivagro strengthening its position.
• New launches well received: Enthusiastic response for insecticide CLARET in paddy, herbicide EKETSU (first-time three-way combination for rice), fungicide KADETT for seed treatment, and bio-fungicide PIILIN for grapes and chili.
• Recovery assumed: Management stated that on an annual basis, there will be growth in domestic revenue, though Q1 is a placement quarter and real consumption starts only in H2 June.

Margins, Tax & Balance Sheet

• Gross margin guided stable: Management expects to maintain gross margin of around 49%-50% in FY25, with FY24 improvement driven by favourable product mix, business mix (higher pharma and CSM export share), and operating leverage.
• EBITDA margin to sustain: EBITDA margins will sustain at current levels as development spending continues in new segments; pharma normalized margins are a post-1.5-year story.
• Tax rate step-up: FY25 ETR expected to increase to up to 24% because the tax exemption for the second SEZ unit at Jambusar reduces from 100% to 50%; this rate continues for FY25 and FY26, with the full holiday expiring after 5 years but extension possible through reinvestment.
• Cash flow and working capital strong: Operating cash flow increased to Rs. 2,035.9 cr; trade working capital reduced to 59 days from 79 days; inventory reduced to ~62 days; surplus cash net of debt stands at Rs. 3,882.5 cr.
• Capex budget: Rs. 800-900 crore capex planned for the current fiscal, with the usual lag between budget and actual spend/capitalization.

Guidance & Commitments

Key Metrics